PROJECTED LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES MELLITUS TREATED WITH FASTER-ACTING INSULIN ASPART VERSUS CONVENTIONAL INSULIN ASPART IN THE UK SETTING

被引：0
|
作者：
Russell-Jones, D. [1 ]
Buchs, S. [2 ]
Jensen, M. M. [2 ]
Hunt, B. [3 ]
Valentine, W. J. [3 ]
Heller, S. [4 ]
机构：
[1] Royal Surrey Cty Hosp, Guildford, Surrey, England
[2] Novo Nordisk AS, Soborg, Denmark
[3] Ossian Hlth Econ & Commun, Basel, Switzerland
[4] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1869
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB39
引用
收藏
页码：A671 / A671
页数：1
相关论文
共 50 条
  • [1] Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting
    Russell-Jones, David
    Heller, Simon R.
    Buchs, Sarah
    Sandberg, Anna
    Valentine, William J.
    Hunt, Barnaby
    DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1773 - 1780
  • [2] Faster-acting insulin aspart improves postprandial glycaemia versus insulin aspart in patients with type 1 diabetes mellitus
    Heise, T.
    Haahr, H.
    Jensen, L.
    Erichsen, L.
    Hompesch, M.
    DIABETOLOGIA, 2014, 57 : S57 - S57
  • [3] FASTER-ACTING INSULIN ASPART IMPROVES POSTPRANDIAL GLYCAEMIA VERSUS INSULIN ASPART IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
    Heise, T.
    Haahr, H.
    Jensen, L.
    Erichsen, L.
    Hompesch, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A5 - A6
  • [4] A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
    Heise, Tim
    Hoevelmann, Ulrike
    Zijlstra, Eric
    Stender-Petersen, Kirstine
    Jacobsen, Jacob Bonde
    Haahr, Hanne
    DRUGS & AGING, 2017, 34 (01) : 29 - 38
  • [5] A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Ulrike Hövelmann
    Eric Zijlstra
    Kirstine Stender-Petersen
    Jacob Bonde Jacobsen
    Hanne Haahr
    Drugs & Aging, 2017, 34 : 29 - 38
  • [6] Faster-Acting Insulin Aspart vs. Insulin Aspart for Adults with Type 1 Diabetes Treated with Insulin Pump and Continuous Glucose Monitoring
    Ranjan, Ajenthen G.
    Schmidt, Signe
    Andersen, Hanne-Charlotte
    Norgaard, Kirsten
    DIABETES, 2024, 73
  • [7] Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus
    Fath, Maryam
    Danne, Thomas
    Biester, Torben
    Erichsen, Lars
    Kordonouri, Olga
    Haahr, Hanne
    PEDIATRIC DIABETES, 2017, 18 (08) : 903 - 910
  • [8] Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
    Heise, Tim
    Stender-Petersen, Kirstine
    Hoevelmann, Ulrike
    Jacobsen, Jacob Bonde
    Nosek, Leszek
    Zijlstra, Eric
    Haahr, Hanne
    CLINICAL PHARMACOKINETICS, 2017, 56 (06) : 649 - 660
  • [9] Faster-Acting Insulin Aspart Improves Postprandial Glycemia vs. Insulin Aspart in Patients with Type 1 Diabetes Mellitus (T1DM)
    Heise, Tim
    Haahr, Hanne L.
    Jensen, Lene
    Erichsen, Lars
    Hompesch, Marcus
    DIABETES, 2014, 63 : A34 - A34
  • [10] Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Kirstine Stender-Petersen
    Ulrike Hövelmann
    Jacob Bonde Jacobsen
    Leszek Nosek
    Eric Zijlstra
    Hanne Haahr
    Clinical Pharmacokinetics, 2017, 56 : 649 - 660
12345